The Cleveland Clinic has officially begun recruiting for its study on the metabolic impacts of the Ren-Nu plant-focused ketogenic dietary program for polycystic kidney disease (NCT07454174). This is a significant development because it represents independent validation of the ketogenic approach to PKD management outside of the original Weimbs lab and University of California researchers.
The Ren-Nu program is a structured plant-focused ketogenic diet specifically designed for PKD patients, developed based on preclinical evidence showing that ketosis can slow cyst growth. Previous data from 103 patients published in Frontiers in Nutrition (2025) showed promising results including improvements in kidney function markers.
Independent replication at a major academic medical center like the Cleveland Clinic is a critical step in establishing dietary ketosis as a legitimate therapeutic approach for PKD. If results confirm prior findings, it strengthens the case for larger randomized controlled trials.
PKD patients interested in dietary interventions have been following the ketogenic approach closely since the landmark 2019 Cell Metabolism paper demonstrated that ketosis inhibits cyst growth in animal models. This Cleveland Clinic study bridges the gap between those preclinical findings and the growing real-world evidence.